RadNet's adjusted EBITDA grew 36.3% year-over-year in Q1 2026, outpacing revenue growth of 22.1%.1 The gap is a margin story, not just a volume one — and it is drawing attention beyond the United States.
Advanced imaging's share of procedural volume rose from 26.9% to 29.3%.1 PET/CT volume climbed 35.2%. MRI same-center volume increased 10.1%, well above the industry baseline.
RadNet credited TechLive, its AI scheduling platform, as a direct driver of MRI utilization gains.1 TechLive fills appointment gaps and reduces scanner downtime, converting idle capacity into billable procedures. Imaging center EBITDA margin improved 188 basis points year-over-year.1
DeepHealth, RadNet's AI diagnostic suite, assists radiologists by flagging findings and prioritizing worklists.1 The two platforms address opposite ends of the workflow: TechLive handles scheduling, DeepHealth handles reading and reporting.
The results arrive as health systems globally struggle with imaging backlogs. The UK's NHS faces radiology wait times exceeding six weeks for many scans. Germany, Japan, and Australia are each investing in AI-assisted diagnostics to address radiologist shortages. RadNet's Q1 data gives those conversations a financial reference point.
The pattern is consistent with what AI deployment looks like at scale: scheduling optimization cuts per-scan overhead; diagnostic AI compresses read times. Both effects compound across a large multi-site network.
Whether TechLive and DeepHealth are the primary causal drivers — rather than volume mix or favorable market conditions — has not been formally isolated.1 A center-by-center comparison of fully deployed versus rollout-phase locations would clarify the contribution. RadNet has not published that breakdown.
What Q1 2026 does establish: a large radiology operator running AI across scheduling and diagnostics is producing margin expansion that volume growth alone does not explain. For hospital networks from London to Tokyo evaluating AI investment, that is a concrete benchmark.
